Predictive Biosciences  
癌症分子诊断
Predictive  Biosciences develops novel molecular diagnostic cancer assays and provides molecular pathology services for urology-based practices. Leveraging a portfolio of patented biomarkers and clinical approaches, the company has built a unique portfolio of assays for cancer management, first targeted at bladder and prostate cancer. The company is backed by leading investors, including Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures, New Enterprises Associates, Inc. (NEA) and ProQuest Investments.